The contract research organization said it has already used CRISPR/Cas9 editing in several customer projects and also plans to use it for internal R&D.
Scientists introduced an indel to a promoter region to mimic a benign, naturally-occurring mutation that activated fetal hemoglobin production.
A new study suggests CRISPR/Cas9-based gene activation can manipulate particular epigenomic patterns found in differentiated cells.
Editas has paid $1 million to test-drive Adverum's viral vectors in clinical gene editing and $1 million for an option on an exclusive license.
CRISPR is the paradigm now in research applications, but companies with IP rights to TALENs and zinc finger nucleases are pushing forward with those technologies.
In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.
The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.
An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.
In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.